Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71−0.06 (-1.59%)
Close on Nov 16, 2026Market cap $283.06MP/E –Yield –
Fulcrum Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Fulcrum Therapeutics's total assets was $323.95M at Jun 30, 2026. For fiscal 2025 it was $366.28M, up 40.5% from the year before. The highest annual figure on record is $366.28M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.28M | +40.5% |
| FY2024 | Dec 31, 2024 | $260.72M | +1.2% |
| FY2023 | Dec 31, 2023 | $257.69M | +13.7% |
| FY2022 | Dec 31, 2022 | $226.69M | -3.5% |
| FY2021 | Dec 31, 2021 | $235.00M | +81.4% |
| FY2020 | Dec 31, 2020 | $129.58M | +17.3% |
| FY2019 | Dec 31, 2019 | $110.44M | +28.8% |
| FY2018 | Dec 31, 2018 | $85.77M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $323.95M | +41.6% |
| Q1 FY2026 | Mar 31, 2026 | $346.77M | +42.9% |
| Q4 FY2025 | Dec 31, 2025 | $366.28M | +40.5% |
| Q3 FY2025 | Sep 30, 2025 | $214.86M | -23.0% |
| Q2 FY2025 | Jun 30, 2025 | $228.84M | -22.2% |
| Q1 FY2025 | Mar 31, 2025 | $242.65M | +4.3% |
| Q4 FY2024 | Dec 31, 2024 | $260.72M | +1.2% |
| Q3 FY2024 | Sep 30, 2024 | $279.01M | +0.0% |
| Q2 FY2024 | Jun 30, 2024 | $294.26M | -2.0% |
| Q1 FY2024 | Mar 31, 2024 | $232.59M | -27.6% |
| Q4 FY2023 | Dec 31, 2023 | $257.69M | +13.7% |
| Q3 FY2023 | Sep 30, 2023 | $278.88M | +12.5% |
| Q2 FY2023 | Jun 30, 2023 | $300.33M | +53.8% |
| Q1 FY2023 | Mar 31, 2023 | $321.12M | +45.8% |
| Q4 FY2022 | Dec 31, 2022 | $226.69M | -3.5% |
| Q3 FY2022 | Sep 30, 2022 | $247.81M | -3.0% |
| Q2 FY2022 | Jun 30, 2022 | $195.23M | +41.6% |
| Q1 FY2022 | Mar 31, 2022 | $220.25M | +40.8% |
| Q4 FY2021 | Dec 31, 2021 | $235.00M | +81.4% |
| Q3 FY2021 | Sep 30, 2021 | $255.55M | +79.7% |
| Q2 FY2021 | Jun 30, 2021 | $137.88M | -4.8% |
| Q1 FY2021 | Mar 31, 2021 | $156.48M | +65.0% |
| Q4 FY2020 | Dec 31, 2020 | $129.58M | +17.3% |
| Q3 FY2020 | Sep 30, 2020 | $142.22M | +22.6% |
| Q2 FY2020 | Jun 30, 2020 | $144.86M | +122.3% |
| Q1 FY2020 | Mar 31, 2020 | $94.86M | +10.6% |
| Q4 FY2019 | Dec 31, 2019 | $110.44M | – |
| Q3 FY2019 | Sep 30, 2019 | $115.96M | – |
| Q2 FY2019 | Jun 30, 2019 | $65.15M | – |
| Q4 FY2018 | Dec 31, 2018 | $85.77M | – |
See a number that looks wrong?